328 related articles for article (PubMed ID: 16314638)
1. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E
J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638
[TBL] [Abstract][Full Text] [Related]
2. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Derks JL; van Suylen RJ; Thunnissen E; den Bakker MA; Groen HJ; Smit EF; Damhuis RA; van den Broek EC; Speel EM; Dingemans AC;
Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572122
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
[TBL] [Abstract][Full Text] [Related]
5. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
7. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
[TBL] [Abstract][Full Text] [Related]
8. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
Naidoo J; Santos-Zabala ML; Iyriboz T; Woo KM; Sima CS; Fiore JJ; Kris MG; Riely GJ; Lito P; Iqbal A; Veach S; Smith-Marrone S; Sarkaria IS; Krug LM; Rudin CM; Travis WD; Rekhtman N; Pietanza MC
Clin Lung Cancer; 2016 Sep; 17(5):e121-e129. PubMed ID: 26898325
[TBL] [Abstract][Full Text] [Related]
9. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
[TBL] [Abstract][Full Text] [Related]
10. Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
Abedallaa N; Tremblay L; Baey C; Fabre D; Planchard D; Pignon JP; Guigay J; Pechoux CL; Soria JC; de Montpreville VT; Besse B
J Thorac Oncol; 2012 Jul; 7(7):1179-83. PubMed ID: 22617247
[TBL] [Abstract][Full Text] [Related]
11. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
Sun JM; Ahn MJ; Ahn JS; Um SW; Kim H; Kim HK; Choi YS; Han J; Kim J; Kwon OJ; Shim YM; Park K
Lung Cancer; 2012 Aug; 77(2):365-70. PubMed ID: 22579297
[TBL] [Abstract][Full Text] [Related]
13. Kit expression in small cell carcinomas of the lung: effects of chemotherapy.
Rossi G; Cavazza A; Marchioni A; Migaldi M; Bavieri M; Facciolongo N; Petruzzelli S; Longo L; Tamberi S; Crinò L
Mod Pathol; 2003 Oct; 16(10):1041-7. PubMed ID: 14559988
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
15. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.
Yamazaki S; Sekine I; Matsuno Y; Takei H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T; Kodama T; Asamura H; Tsuchiya R; Saijo N
Lung Cancer; 2005 Aug; 49(2):217-23. PubMed ID: 16022916
[TBL] [Abstract][Full Text] [Related]
16. High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma.
Sun L; Sakurai S; Sano T; Hironaka M; Kawashima O; Nakajima T
Pathol Int; 2009 Aug; 59(8):522-9. PubMed ID: 19627535
[TBL] [Abstract][Full Text] [Related]
17. The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung.
Kujtan L; Muthukumar V; Kennedy KF; Davis JR; Masood A; Subramanian J
J Thorac Oncol; 2018 May; 13(5):707-714. PubMed ID: 29391287
[TBL] [Abstract][Full Text] [Related]
18. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
[TBL] [Abstract][Full Text] [Related]
19. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
Christopoulos P; Engel-Riedel W; Grohé C; Kropf-Sanchen C; von Pawel J; Gütz S; Kollmeier J; Eberhardt W; Ukena D; Baum V; Nimmrich I; Sieder C; Schnabel PA; Serke M; Thomas M
Ann Oncol; 2017 Aug; 28(8):1898-1902. PubMed ID: 28535181
[TBL] [Abstract][Full Text] [Related]
20. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
